While these proof-of-concept experiments were carried out with RAC1 mutations (i.e., RAC1G12C, alone or combined as RAC1G12C, K96H) that are rarely if ever encountered in human cancer, they point to the possibility of developing targeted inhibitors that act directly on cancer-relevant mutants such as RAC1G12V and RAC1P29S [157]. This evidence concerns the gene RAC1 and cancer.